Table 4:
Multivariable analyses for events by 2 years
| Variable | N | Hazard Ratio [99% CI] |
p-value |
|---|---|---|---|
|
Overall Mortality (adjusted for center effects)
| |||
| Main Effect Variable, Infection | 0.0017 | ||
| SibCNI, no infection | 1421 | 1.00 | |
| HaploCy with infection | 114 | 1.65 [1.11 – 2.43] | 0.0010 |
| SibCy with infection | 65 | 1.48 [0.96 – 2.27] | 0.0203 |
| SibCNI with infection | 148 | 1.13 [0.84 – 1.53] | 0.2787 |
| HaploCy no infection | 615 | 1.25 [0.97 – 1.61] | 0.0246 |
| SibCy no infection | 330 | 1.20 [ 0.70 – 1.47] | 0.8979 |
|
| |||
| Disease/Stage/Cytogenetics (IPSS) | < 0.0001 | ||
| AL, early/intermediate, favorable cyto | 68 | 1.00 | |
| AL early, normal/intermediate cyto | 667 | 1.00 [0.56–1.78] | 0.9892 |
| AL early, poor cyto | 434 | 0.96 [0.55–1.69] | 0.8655 |
| AL intermediate, normal/intermediate cyto | 213 | 1.07 {0.59 – 1.92] | 0.7695 |
| AL intermediate, poor cyto | 124 | 1.27 [0.69 – 2.33] | 0.3208 |
| AL advanced, any cyto | 291 | 1.97 [1.08 – 3.60] | 0.0036 |
| MDS very low/low | 307 | 0.90 [0.51 – 1.59] | 0.6248 |
| MDS intermediate | 229 | 1.54 [ 0.87 – 2.72] | 0.0539 |
| MDS high/very high | 162 | 2.05 [ 1.09 – 3.86] | 0.0034 |
| Missing | 198 | 1.29 [ 0.66 – 2.50] | 0.3255 |
|
| |||
| HCT-CI | 0.0004 | ||
| 0 | 679 | 1.00 | |
| 1 – 2 | 762 | 0.95 [0.67 – 1.34] | 0.6945 |
| 3 – 4 | 768 | 1.12 [ 0.80 – 1.56] | 0.3815 |
| 5+ | 484 | 1.32 [ 0.94 – 1.85] | 0.0380 |
|
| |||
| Age at HCT, years | <0.0001 | ||
| 0 – 20 | 234 | 1.00 | |
| 21 – 40 | 479 | 0.88 [0.60 – 1.30] | 0.4042 |
| 41 – 60 | 945 | 1.27 [0.89 – 1.82] | 0.0790 |
| 60 | 1035 | 1.62 [1.08 – 2.42] | 0.0023 |
|
| |||
|
Treatment Related Mortality (adjusted for center effects)
| |||
| Main Effect Variable, Infection | 0.0164 | ||
| SibCNI, no infection | 1415 | 1.00 | |
| HaploCy with infection | 116 | 2.14 [1.13 – 4.07] | 0.0022 |
| SibCy with infection | 65 | 1.84 [ 0.80 – 4.21] | 0.0574 |
| SibCNI with infection | 146 | 1.52 [0.95 – 2.43] | 0.0223 |
| HaploCy no infection | 621 | 1.42 [0.86 – 2.35] | 0.0736 |
| SibCy no infection | 329 | 1.15 [ 0.56 – 2.36] | 0.6290 |
|
| |||
| Donor/Recipient Gender Match | <0.0001 | ||
| Male/Male | 927 | 1.00 | |
| Male/Female | 616 | 1.05 [0.77 – 1.43] | 0.6610 |
| Female/Male | 658 | 1.45 [1.13 – 1.87] | 0.0002 |
| Female/Female | 491 | 0.82 [0.56 – 1.19] | 0.1631 |
|
| |||
| Age at HCT, years | 0.0025 | ||
| 0 – 20 | 234 | 1.00 | |
| 21 – 40 | 477 | 0.80 [0.47 – 1.37] | 0.2857 |
| 41 – 60 | 946 | 1.23 [ 0.68 – 2.25] | 0.3673 |
| > 60 | 1035 | 1.77 [ 0.88 – 3.55] | 0.0341 |
|
| |||
| Acute GVHD, grade II-IV | <0.0001 | ||
| No | 1837 | 1.00 | |
| Yes | 855 | 2.66 [ 1.79 – 3.96] | |
|
| |||
|
Relapse (adjusted for center effects)
| |||
| Main Effect Variable, Infection | 0.1185 | ||
| SibCNI, no infection | 1407 | 1.00 | |
| HaploCy with infection | 113 | 1.39 [0.99 – 1.96] | 0.0118 |
| SibCy with infection | 65 | 1.03 [0.58 – 1.84] | 0.8883 |
| SibCNI with infection | 146 | 0.72 [0.44 – 1.20] | 0.0992 |
| HaploCy no infection | 605 | 1.08 [0.79 – 1.46] | 0.5416 |
| SibCy no infection | 326 | 1.08 [0.76 – 1.55] | 0.5700 |
|
| |||
| Disease/Stage/Cytogenetics (IPSS) | <0.0001 | ||
| AL, early/intermediate, favorable cyto | 67 | 1.00 | |
| AL early, normal/intermediate cyto | 659 | 0.69 [0.40 – 1.21] | 0.0890 |
| AL early, poor cyto | 430 | 0.96 [0.54 – 1.70] | 0.8366 |
| AL intermediate, normal/intermediate cyto | 208 | 0.75 [0.43 – 1.33] | 0.1945 |
| AL intermediate, poor cyto | 124 | 1.03 [0.55 – 1.94] | 0.8889 |
| AL advanced, any cyto | 289 | 2.00 [1.18 – 3.40] | 0.0007 |
| MDS very low/low | 305 | 1.03 [0.61 – 1.76] | 0.8827 |
| MDS intermediate | 227 | 1.20 [0.67 – 2.16] | 0.4246 |
| MDS high/very high | 159 | 2.27 [1.25 – 4.10] | 0.0004 |
| Missing | 194 | 1.12 [0.62 – 2.01] | 0.6141 |
|
| |||
| Conditioning Intensity | <0.0001 | ||
| Myeloablative | 1419 | 1.00 | |
| RIC/NMA | 1243 | 1.46 [1.23 – 1.73] | |
|
| |||
| Acute GVHD, grade II-IV | <0.0001 | ||
| No | 1816 | 1.00 | |
| Yes | 846 | 0.78 [0.67 – 0.91] | |
|
| |||
|
Chronic GVHD (adjusted for center effects)
| |||
| Main Effect Variable, Infection | <0.0001 | ||
| SibCNI, no infection | 1433 | 1.00 | |
| HaploCy with infection | 117 | 1.09 [0.71 – 1.67] | 0.6031 |
| SibCy with infection | 65 | 0.73 [0.42 – 1.25] | 0.1283 |
| SibCNI with infection | 148 | 1.13 [0.78 – 1.65] | 0.3971 |
| HaploCy no infection | 632 | 0.56 [0.40 – 0.77] | <0.0001 |
| SibCy no infection | 332 | 0.61 [0.41 – 0.92] | 0.0017 |
|
| |||
| Graft Type | <0.0001 | ||
| Bone Marrow | 636 | 1.00 | |
| Peripheral Blood | 2091 | 2.23 [1.66 – 3.00] | |
|
| |||
| Donor/Recipient Gender Match | 0.0005 | ||
| /Male | 937 | 1.00 | |
| Male/Female | 623 | 1.01 [0.82 – 1.25] | 0.8804 |
| Female/Male | 670 | 1.26 [1.04 – 1.54] | 0.0021 |
| Female/Female | 496 | 1.24 [1.01 – 1.53] | 0.0074 |
|
| |||
| Acute GVHD, grade II-IV | 0.0004 | ||
| No | 1820 | 1.00 | |
| Yes | 907 | 1.30 [1.07 – 1.58] | |